Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma

Melanoma Research

Volumn 8, Issue 2, 1998, Pages 170-174

  Richard, M A ^a   Grob, J J ^a   Zarrour, H ^a   Besseres N ^a   Bizzari, J P ^b   Gerard B ^b   Bonerandi, J J ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cisplatin; Dacarbazine; Eligibility criteria; Fotemustine; Melanoma; Metastatic melanoma; Tamoxifen

Indexed keywords

CISPLATIN; DACARBAZINE; FOTEMUSTINE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MALE; MELANOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0031922061     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199804000-00012     Document Type: Article

References (16)

1. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous Melanoma, 2nd edn. Philadelphia: JB Lippincot, 1992: 498-508.
2. Avril MF. Chimiothérapies. In: Delaunay MM, ed. Melanome Cutané. Paris: Masson Ed, 1992: 133-140.
3. Del Prete SA, Maurer LH, O'Donnell J, et al. Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 1403-1405.
4. Lattanzi SC, Tosteson T, Cherloff J, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5 years follow-up. Melanoma Res 1995; 5: 365-369.
5. McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987; 71: 465-469.
6. McClay EF, Mastrangelo MJ, Sprandio JD, et al. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989; 63: 1292-1295.
7. McClay EF, Mastrangelo MJ, Berd D, et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50: 553-556.
8. Ramirez G, Wilson W, Grage T, et al. Phase II evaluation of 1-3 bis (2 chloroethyl nitrosurea) (BCNU: NSC-409962) in patients with solid tumors. Cancer Chemother Rep 1972; 1: 169-170.
9. Jacquillat C, Khayat D, Banzet P, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25: 263-266.
10. Jacquillat C, Khayat D, Banzet P, et al. Final report of phase II study of the nitrosourea fotemustine (S 10036) in 153 patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-1878.
11. Kleeberg UR, Engel E, Israels P, et al. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group. Melanoma Res. 1995; 5: 195-200.
12. Avril MF, Bonneterre J, Delaunay M, et al. Combination chemotherapy with fotemustine and dacarbazine in disseminated malignant melanoma: results of the French Multicentric Study. Cancer Chemother Pharmacol 1990; 27: 81-84.
13. Merinsky O, Inbar M, Chaitchik S. Fotemustine and DTIC combination in patients with disseminated melanoma. Am J Clin Oncol 1992; 15: 84-86.
14. Aamdal L, Gerard B, Bohman T, et al. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma - an effective combination with unexpected toxicity. Eur J Cancer 1992; 28: 447-450.
15. Gehan EA. The determination of the number of patients required in a follow-up trial of a new chemotactic agent. J Chron Dis 1961; 13: 346-353.
16. Khayat D, Lokiek, Bizzari JP. Phase I clinical study of the new amino-acid linked nitrosurea S-10036 administered on a weekly schedule. Cancer Res 1987; 47: 6782-6785.